Measures currently being taken against COVID-19 are the only means of containing and suppressing the virus. Until a vaccine is made and tested, progress will remain slow. As we’ve seen over the past month, the concerns around this novel coronavirus will only grow as markets around the world are getting crushed.
China first faced the outbreak of the novel coronavirus, and now it has spread across the world. Global infections of roughly 394,000 people have been reported. There are currently 273,000 active cases of the coronavirus and over 120,000 closed cases. Of those with outcomes, nearly 103,000 of those infected have recovered, while about 17,000 deaths have been reported.
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and where their stocks stand now.
Mylan N.V. (NASDAQ: MYL) stock was up over 4% at $16.47 on Tuesday, in a 52-week range of $12.75 to $28.88. The consensus price target is $23.93.
Novavax Inc. (NASDAQ: NVAX) traded up about 25% to $13.43, in a 52-week range of $3.54 to $17.71. The consensus price target is $14.00.
Aytu BioScience Inc. (NASDAQ: AYTU) shares were up 7.5% to $2.01. The 52-week range is $0.34 to $2.99, and the consensus price target is $4.88.
Altimmune Inc. (NASDAQ: ALT) shares were up less than 1% to $2.97, in a 52-week range of $1.51 to $4.45. The consensus price target is $13.00.
NanoViricides Inc. (NYSE: NNVC) stock pushed 4% lower to $5.88. The 52-week range is $1.27 to $19.20.
Moderna Inc. (NASDAQ: MRNA) shares traded down 7% at $24.70, in a 52-week range of $11.54 to $36.00. The consensus price target is $33.44.
Inovio Pharmaceuticals Inc. (NASDAQ: INO) shares were up 6% at $7.03. The 52-week range is $1.92 to $19.36, and the consensus price target is $10.43.
Gilead Sciences Inc. (NASDAQ: GILD) shares were up about 1% at $73.35. The 52-week range is $60.89 to $85.97. The consensus price target is $74.91.
Sanofi (NASDAQ: SNY) shares were up about 4% at $40.19, in a 52-week range of $37.62 to $51.84. The consensus price target is $56.88.
Quest Diagnostics Inc. (NYSE: DGX) stock was up about 4% at $78.06, in a 52-week range of $73.21 to $118.58. The consensus price target is $110.43.
Co-Diagnostics Inc. (NASDAQ: CODX) stock was down 12% at $8.30. It has a 52-week range of $0.69 to $21.75 and a consensus analyst target of $19.00.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) was down about 1% at $452.20, with a 52-week range of $271.37 to $518.00. The consensus price target is $475.00.
Essential Tips for Investing (Sponsored)
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
